Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial is futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously disappointing, we decided to take a calculated risk on this program and with the carefully staged agreement, we have spent a total of $15 million, a relatively modest amount for a late Phase 3 asset addressing a large market opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain dedicated to advancing our development pipeline by making investments in future growth and continue to look for attractive late-stage in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a divis
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
(Date:6/18/2013)... 2013 Tabletop SEMs are inexpensive and ... have limited performance and capability such as small sample ... would normally provide better imaging performance and more analytical ... have a higher cost of maintenance. The Pemtron ... these two types of SEM product, offering competitive prices ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
... and ALACHUA, Fla., Sept. 4 ,Zimmer Holdings, Inc. ... in the orthopaedics,industry, and Tutogen Medical, Inc., a ... human (allograft) and animal,(xenograft) tissue, today announced the ... wholly owned subsidiary of Zimmer Holdings,Inc., into Europe, ...
... Ind., Sept. 4 ,Tutogen Medical, Inc. (Amex: ... products made from human (allograft) and animal,(xenograft) tissue, ... a leader,in the orthopaedics industry, today announced the ... wholly owned subsidiary of Zimmer,Holdings, Inc., into Europe, ...
... to Present at BioCentury,s Newsmakers in the Biotech,Industry, Bank of America ... ... Conferences, SEATTLE, Sept. 4 Trubion Pharmaceuticals,Inc. ... executive officer, and chairman of Trubion, will present an overview,of the ...
Cached Biology Technology:Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 2Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 3Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 4Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 5Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 2Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 3Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 4Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 5Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:6/19/2013)... CANTON, Ohio , June 19, 2013 ... implemented advanced clinical laboratory diagnostics technology for ... 1c ) diabetes testing, as well as ... blood cell and platelet counts. The new ... more accurate lab results for physicians and ...
(Date:6/19/2013)... study of the patients who received injections of ... the New England Compounding Center has found that ... did not experience a worsening of their symptoms ... detect infection, especially among those individuals who received ... study, along with an editorial by UC Davis ...
(Date:6/19/2013)... the cover story for the journal Genetics ... University of Massachusetts Amherst describe a new experimental technique ... function of individual proteins in individual cell types in ... deeper insights into protein function, Chase says, "because we ... single protein does when we isolate its function in ...
Breaking Biology News(10 mins):Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 3Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 4Evolution of an outbreak: Complications from contaminated steroid injections 2UMass Amherst researchers develop powerful new technique to study protein function 2UMass Amherst researchers develop powerful new technique to study protein function 3
... in World War II, the Korean War, and the Vietnam ... and obese than men who are non-combat veterans or non-veterans, ... 45th annual Conference of Cardiovascular Disease, Epidemiology and Prevention. , ... heavy drinkers as opposed to never drinkers than non-veterans, and ...
... and wild--are indifferent to sweets. A new study ... their strictly carnivorous behavior. "We took a behavioral ... senior author of the study and Associate Director ... on mammalian tongues are specialized taste bud receptors ...
... The immune system is a complex and powerful weapon ... left unchecked, would wreak havoc throughout the human body. ... body's own tissues is essential, but sometimes the immune ... harmful invaders. This can lead to autoimmune disease characterized ...
Cached Biology News:Male Combat Veterans Rank High In Heart Disease Risk 2New insight into autoimmune disease: Bacterial infections promote recognition of self-glycolipids 2
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: